People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Novasenta Inc. | — | Biotechnology | Series A | $25.0M | $100.6M | 2022 |
| Generian Pharmaceuticals, Inc. | — | Biotech / Pharma | Series A | $13.0M | $435.2M | 2019 |
Matthias Kleinz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthias Kleinz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeanne Cunicelli | 2 | 7 |
| DAVID MOORE | 1 | 13 |
| Mani Mohindru | 1 | 2 |
| Hank Safferstein | 1 | 2 |
| Beibei Chen | 1 | 1 |
| Toren Finkel | 1 | 1 |
| Greg Delgoffe | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.